MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 886 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Fórmula:C31H36ClFN6O2Forma y color:SolidPeso molecular:579.11Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Fórmula:C18H16N2OForma y color:SolidPeso molecular:276.33G-479
CAS:<p>G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.</p>Fórmula:C16H15FIN5O4Forma y color:SolidPeso molecular:487.22MEK4 inhibitor-2
CAS:<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Fórmula:C20H15FN4O3SForma y color:SolidPeso molecular:410.42XMU-MP-9
CAS:<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Fórmula:C19H13ClFN3OSForma y color:SolidPeso molecular:385.84PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Fórmula:C45H68N4OForma y color:SolidPeso molecular:681.05EBI-907
CAS:<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Fórmula:C23H21ClF2N4O3SForma y color:SolidPeso molecular:506.95SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Fórmula:C26H28ClFN6Forma y color:SolidPeso molecular:478.992KRAS inhibitor-21
CAS:<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Fórmula:C33H41N5O3Forma y color:SolidPeso molecular:555.71p38 Kinase inhibitor 8
CAS:<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>Fórmula:C22H21FN6O2Forma y color:SolidPeso molecular:420.44KRASG12D-IN-3-d3
CAS:KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Fórmula:C31H27D3ClF6N7O2Forma y color:SoildPeso molecular:685.08L 739749
CAS:<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Fórmula:C24H41N3O6S2Pureza:98%Forma y color:SolidPeso molecular:531.73LSN3074753
CAS:<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Fórmula:C24H30FN5O2Forma y color:SolidPeso molecular:439.53p38α inhibitor 8
CAS:<p>p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.</p>Fórmula:C17H13FN6Forma y color:SolidPeso molecular:320.324p38 Kinase inhibitor 7
CAS:<p>p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.</p>Fórmula:C22H25FN6OForma y color:SolidPeso molecular:408.472Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Fórmula:C32H30ClFN6O4Pureza:98.04%Forma y color:SolidPeso molecular:617.07p38 MAP Kinase-IN-1
CAS:<p>p38 MAP Kinase-IN-1 (Compound 4) is an inhibitor of p38, suitable for studies related to inflammation and autoimmune responses.</p>Fórmula:C20H19FN6OForma y color:SolidPeso molecular:378.403Coelogin
CAS:<p>Coelogin is an orally effective bone-protective agent that activates ER-Erk and Akt-dependent signaling pathways, thereby stimulating osteoblast differentiation. It is utilized in osteoporosis research.</p>Fórmula:C17H16O5Forma y color:SolidPeso molecular:300.31Casein kinase 1δ-IN-27
CAS:<p>Casein kinase1δ-IN-27 (Compound 8) is an inhibitor of casein kinase 1 (CK1), effectively inhibiting CK1α, CK1δ, CK1ε, and p38α with IC50 values of 22, 16.5, 9.41, and 14.8 nM, respectively. It also suppresses DUX4 expression, with an IC50 of 10 nM.</p>Fórmula:C21H19FN6Forma y color:SolidPeso molecular:374.414JNK-IN-19
CAS:<p>JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.</p>Fórmula:C22H24F3N6Na2O6PForma y color:SolidPeso molecular:602.41
